Harvard case dismissed as hormone study points to lower dementia risk

Full account

A federal lawsuit brought by the US government against Harvard University has moved through the courts this year, according to filings tracked by the Civil Rights Litigation Clearinghouse. The Department of Justice filed suit on 20 March 2026 in the US District Court for the District of Massachusetts, accusing the university of breaching Title VI of the Civil Rights Act of 1964 by failing to protect Jewish and Israeli students from harassment. The complaint alleged that Harvard had been "deliberately indifferent" to hostility directed at these groups and had declined to enforce its own conduct rules when Jewish or Israeli students were the victims. Because the university receives federal grants, the government argued it was bound by Title VI's anti-discrimination requirements, and it sought a court declaration of wrongdoing, an injunction, and the recovery of billions of dollars in federal subsidies it says were paid out while the alleged discrimination was ongoing.

Harvard has characterised the litigation as part of a broader effort by the Trump administration to pressure the university into adopting the government's preferred approach to antisemitism and admissions policy, including matters touching on race. The Clearinghouse's own case record, current at the time of writing, lists the matter as ongoing rather than resolved, which sits awkwardly alongside reports that the case has now been dismissed; readers should treat claims of a final resolution with some caution until confirmed by a more detailed court filing or docket update, since the source record available here does not itself describe the manner in which, or whether, the case concluded.

Away from the courtroom, a separate and unrelated piece of research has drawn attention this month to a possible protective effect of hormone treatment against dementia. A study led by researchers at Stanford Medicine, published on 12 August 2026 in the journal Neurology, found that women who used oestrogen-only menopausal hormone therapy had markedly better outcomes on measures of brain health than women who had never used such treatment. Drawing on two large datasets encompassing more than 21,000 women in total, the team examined both clinical records from living participants and, crucially, post-mortem brain tissue from several thousand others. Women who had taken oestrogen-only therapy were found to have around 39 per cent lower odds of receiving a clinical dementia diagnosis during their lifetime, alongside better performance on memory tests and greater independence in daily functioning. Brain autopsies additionally showed roughly 35 per cent lower odds of the hallmark changes associated with Alzheimer's disease, including amyloid plaques and tau tangles, a pattern corroborated by biomarker tests in blood and spinal fluid from living participants.

The study's authors were keen to stress the limits of what the findings show. Jennifer Bruno of Stanford Medicine, one of the lead researchers, cautioned that the results demonstrate an association rather than proof that hormone therapy prevents dementia, and noted that the women studied had typically begun treatment decades ago, often after the age of 70 and using formulations and timing that differ from current prescribing practice — meaning the findings may not translate directly to how hormone therapy is used today. The coverage varies somewhat in emphasis: Stanford's own reporting foregrounds the novelty of examining autopsy-confirmed brain pathology, described by senior author Hadi Hosseini as the "gold standard" missing from earlier research, and the fact that prior studies had linked hormone therapy to increased dementia risk. ScienceDaily's account, sourced from the American Academy of Neurology, places more weight on the scale of the study and on the researchers' caveat that this was oestrogen-only therapy, generally prescribed to women who have had a hysterectomy, whereas earlier studies flagging increased risk had often involved combined oestrogen-progestin regimens — an important distinction that separates this study's findings from the broader, more cautious picture painted by past research into hormone therapy and the brain.

Where outlets differ

Source 1 (the Civil Rights Litigation Clearinghouse) describes the Harvard case as 'Ongoing' with no mention of a dismissal, which is at odds with the supplied headline's claim that the case has been dismissed — this account flags that discrepancy rather than asserting a resolution not supported by the source text.

Source 1 presents both sides' framing: the government's Title VI discrimination allegations versus Harvard's characterisation of the suit as political coercion over antisemitism and admissions policy.

Stanford Medicine's own report emphasises the methodological novelty of using autopsy-confirmed Alzheimer's pathology as a 'gold standard' outcome, quoting senior author Hadi Hosseini at length on why this approach is unique.

ScienceDaily/American Academy of Neurology's summary leads with the topline statistics (39% and 35% lower odds) and gives more prominence to lead author Jennifer Bruno's caveats about the study reflecting decades-old hormone therapy practices rather than current prescribing standards.

Only the estrogen-only therapy formulation was studied in both science sources; both explicitly distinguish this from combined estrogen-progestin therapy, which earlier research had associated with higher dementia risk.

• clearinghouse.net
• med.stanford.edu
• www.sciencedaily.com